Author:
Ma Cheng-Xu,Ma Xiao-Ni,Guan Cong-Hui,Li Ying-Dong,Mauricio Dídac,Fu Song-Bo
Abstract
AbstractCardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Funder
the Lanzhou Chengguan District Science and Technology Plan Project
the hospital fund of the First Hospital of Lanzhou University
the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases
the Special Funds of Science and Technology Development of the Chinese Central Government to guide Local
the Gansu Provincial Natural Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism
Reference137 articles.
1. Diabetes. World Health Organization 2021, https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 10 Nov 2021.
2. World health statistics 2020: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization 2020. Licence: CC BY-NC-SA 3.0 IGO.
3. World health statistics 2021: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization 2021. Licence: CC BY-NC-SA 3.0 IGO.
4. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83–83.
5. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021. https://doi.org/10.1038/s41580-021-00390-6.